How to calculate indirect costs in economic evaluations - The author's reply

被引：0
|
作者：
Liljas, B [1 ]
机构：
[1] Univ Lund, Dept Econ, Lund, Sweden
来源：
PHARMACOECONOMICS | 1998年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：566 / 569
页数：4
相关论文
共 50 条
  • [21] How Flemish is it? (Author's reply to reader's comments)
    Judt, T
    [J]. NEW YORK REVIEW OF BOOKS, 2001, 48 (08) : 69 - 69
  • [22] Distributional consequences of including survivor costs in economic evaluations distributional consequences of survivor costs in economic evaluations
    Kellerborg, Klas
    Brouwer, Werner
    Versteegh, Matthijs
    Wouterse, Bram
    van Baal, Pieter
    [J]. HEALTH ECONOMICS, 2021, 30 (10) : 2606 - 2613
  • [23] Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs
    Bebo, Bruce F.
    [J]. NEUROLOGY, 2022, 99 (18) : 819 - 819
  • [24] HOW TO REFORM INDIRECT COSTS
    CRAMER, JG
    [J]. PHYSICS TODAY, 1981, 34 (01) : 9 - &
  • [25] HOW TO CALCULATE THE MAXIMUM RISK - REPLY
    INBAL, A
    EPSTEIN, O
    BLICKSTEIN, D
    KORNBROT, N
    BRENNER, B
    MARTINOWITZ, U
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1994, 5 (05) : 851 - 851
  • [26] HOW TO CALCULATE AND CONTROL WELDING COSTS.
    Myers, L.W.
    [J]. Welding Design and Fabrication, 1978, 51 (11): : 78 - 86
  • [27] How relevant are social costs in economic evaluations? The case of Alzheimer's disease (vol 20, pg 1207, 2019)
    Pena-Longobardo, L. M.
    Rodriguez-Sanchez, B.
    Oliva-Moreno, J.
    Aranda-Reneo, I.
    Lopez-Bastida, J.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2021, 22 (05): : 849 - 849
  • [28] How much is the cost of visual impairment: the author's reply
    Lafuma, A
    [J]. PHARMACOECONOMICS, 2006, 24 (02) : 210 - 210
  • [29] How to set up a perineal clinic Author's reply
    Fowler, G.
    [J]. OBSTETRICIAN & GYNAECOLOGIST, 2009, 11 (03): : 222 - 222
  • [30] How Much is the Cost of Visual Impairment: the Author’s Reply
    Antoine Lafuma
    [J]. PharmacoEconomics, 2006, 24 : 210 - 210
12345